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Gastric cancer represents the third most common cause of cancer
deaths in Italy (Decarli and La Vecchia, 1988). Following curative
surgery, patients with nodal involvement have an 85–90% proba-
bility of dying within 5 years (Davis et al, 1990), with a median
survival of 8 months (Alexander et al, 1997). Yet, even today,
adjuvant chemotherapy of gastric cancer after curative resection
remains controversial. In 1996, our group published preliminary
positive survival results of a randomized trial in favour of the use
of adjuvant chemotherapy versus no further treatment in resected
gastric cancer patients (Neri et al, 1996).
Here we present the results of our trial update with more
patients accrued and longer follow-up (5 years), that compared
EPI-LV-5FU adjuvant chemotherapy versus no treatment on
resected, node-positive gastric cancer patients.
PATIENTS AND METHODS
In our earlier study (Neri et al, 1996), we presented data derived
from 55 patients comprising the control group (Arm A) and 48
patients treated with the EPI-LV-5FU adjuvant chemotherapy
protocol (Arm B) based on an interim analysis after 36 months of
observation. In this report, we provide the complete data on all 137
patients enrolled, after a 5-year follow-up period. Patients were
entered into the study by 6 centres in Italy and all had histo-
logically confirmed gastric adenocarcinoma without clinical or
radiologic evidence of distant metastases, a Karnofsky score
greater than 60 and past good general health with no history of
cardiac disorder or congestive heart failure. Table 1 outlines
clinical characteristics of the patients and their tumour stage. All patients were aware of the investigational nature of the treatment
and had given written informed consent, in line with institutional
regulations. Full staging of patients was carried out before they
entered into the trial. In the randomization carried out 4–6 weeks
following gastric resection, patients were stratified by centre to
receive either postoperative chemotherapy with Epidoxorubicin
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Table 1 Clinical characteristics of patients
Treatment arm
Control Chemotherapy
(arm A) (arm B)
Evaluable patients 68 69
Median age (range) 64 (35–74) 62 (37–73)
Sex
Male 48 50
Female 20 19
Site of primary tumour
Pylorus or antrum 25 23
Body 31 29
Cardia or fundus 12 17
T stagea
T1 1 2
T2 6 9
T3 33 31
T4 28 27
N stagea
N1 30 35
N2 38 34
Surgery
R-1A resection 21 23
R-1B resection 37 37
R-2 resection 10 9
Karnofsky score
³ 80 35 39
< 80 33 30
aInternational Union Against Cancer (1987)
http://www.bjcancer.com(EPI) 75 mg/m2 day 1 and Leucovorin (LV) 200 mg/m2 plus
5-fluorouracil (5-FU) 450 mg/m2 days 1–3 or control follow-up.
Patients in both groups were evaluated at 8-week intervals during
the first postoperative year, at 3-month intervals during the second
and third years and at 6-month intervals in the fourth and fifth
years. Treatments, evaluation of toxic effects and follow-up were
carried out as reported previously (Neri et al, 1996). Postoperative
5-year survival was determined for all patients and was measured
from the date of randomization to death or last follow-up.
Statistics
Life-table estimates were computed using life-table options from a
univariate analysis and were compared using the log-rank test and
an estimate of the hazard ratio (HR) provided with associated
confidence intervals. To rule out covariates, we tested the differ-
ences in frequencies in the two patient groups (Arm A and B) by
contingency table analysis (SAS Institute, 1987).
RESULTS
This is the second and final publication on 137 randomized
patients with gastric cancer after a 5-year follow-up period. A total
of 402 chemotherapy cycles were recorded. 61 patients (88%)
received all of the planned 7 cycles of the EPI-LV-5-FU schedule.
Two patients developed severe myelosuppression and completed
only 4 and 5 cycles respectively, with an attenuated dose. Three
patients refused to go on with therapy after the fourth cycle and
one after the fifth cycle. Two others relapsed after the third and
fourth cycle and died 7 and 9 months after the onset of treatment.
The total observation period extended over 5 years. The median
survival time for the 68 untreated patients was 18 months (range
2–60+). The 69 treated patients had a median survival time of
31 months (7–60+), a significant increase (P < 0.01), and HRs
calculated for the whole period of observation support these
findings (Table 2). In the control group 59 out of 68 patients died
because of recurrence vs 48 out of 69 in the adjuvant EPI-LV-5-FU
treated group. Survival time and the proportion of patients alive by
the end of 60 months of observation are reported in Figure 1.
Our multivariate analysis took into account 3 potentially
confounding factors: stage, lymph node status and type of surgery.
We obtained the following results: P > 0.33 for stage; P > 0.43 for
lymph node status and P > 0.75 for surgery, leading us to conclude
that treatment was the only significant prognostic factor.
Toxicity scores among patients are listed in Table 3.
Myelosuppression tended to be cumulative, with lower and more
prolonged nadirs after 5 cycles. Severe leucopenia affected only 5
patients. None of our patients required hospitalization for sepsis,
and 10 who experienced infection (mainly pulmonary) were all
manageable on an outpatient basis.
DISCUSSION
In Western countries, postoperative gastric cancer adjuvant strate-
gies have until now not succeeded in improving overall survival
(Coombes et al, 1990; Kelsen, 1996), even though the Japanese
data strongly suggest that adjuvant chemotherapy should be an
integral part of the treatment of patients with gastric cancer after
curative resection. In fact their data appear so convincing that,
since 1982, they have abolished the control group in their
studies (Nakajima and Nishi, 1989). Along with others (The
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Table 2 Hazard ratioa and confidence limits
Treatment Hazard LCLb UCLb
Arm A 1.96 1.32 2.92
Arm B 1.00 – –
aAnalysis for 60 months of follow-up. b95% Confidence limits. Arm A:
controls. Arm B: treated patients.
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Figure 1 Survival distribution of patients following surgery. The number of
patients (risk set) is shown beneath the time axis. Arm A, controls; arm B,
treated patients.
Table 3 Grade of toxicity according to World Health Organization
Grade Grade 3 or 4 toxicity
0 1 2 3 4 Incidence Percentage
Emesis 25 27 17 – – – –
Diarrhoea 17 28 18 6 – 6/69 (8.7)
Mucositis 18 23 20 8 – 8/69 (12.0)
Alopecia 14 23 32 – – – –
Cardiac 25 30 14 – – – –
Hepatic 25 22 12 – – – –
Neurological 35 34 – – – – –
Renal 30 34 5 – – – –
Anaemia 21 25 20 3 – 3/69 (4.3)
Leucopenia 20 21 22 5 1 6/69 (8.7)
Thrombopenia 21 28 18 2 – 2/69 (2.9)880 B Neri et al
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Gastrointestinal Tumor Study Group, 1982; Michelassi et al,
1994), we considered the presence of lymph node involvement a
highly unfavourable prognostic factor for gastric cancer patients,
hence one requiring adjuvant treatment. The results of our study
after 5 years confirm our previous findings (Neri et al, 1996) and
the conclusions of a more recent meta-analysis (Earle et al 1998)
that adjuvant chemotherapy produces a small survival benefit in
patients with curatively resected gastric carcinoma. Those with
lymph node metastases have a higher risk of recurrence and may
derive more absolute benefit from the treatment. In the future, to
better select patients with a greater likelihood of profiting from
adjuvant chemotherapy, we intend to supplement data on lymph
node involvement with an analysis of the tumour’s biomolecular
characteristics (Yonemura et al, 1996; Fenoglio-Preiser, 1997)
based on the study of its cellular proliferation, invasion and resis-
tance to chemotherapy. We hope that our results will be confirmed
on larger samples and, if possible, improved with more active
treatment schedules.
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